Viracta Therap 
Welcome,         Profile    Billing    Logout  
 7 Products   73 Diseases  7 Products   2 Trials   399 News 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ojemda (tovorafenib) / Day One Biopharma
LOGGIC, NCT05566795 / 2022-001363-27: DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (/FIREFLY-2)

Recruiting
3
400
Europe, Canada, US, RoW
Tovorafenib, DAY101, Ojemda, Chemotherapeutic Agent, COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin
Day One Biopharmaceuticals, Inc., SIOPe Brain Tumor Group LOGGIC Consortium
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
02/26
03/30
2020-003657-30: A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer

Ongoing
2
60
Europe
DAY101, Tablet
DOT Therapeutics-1 Inc. (Day One), DOT Therapeutics-1 Inc. (Day One)
BRAF-Altered, Recurrent or Progressive Low-Grade Glioma in pediatric patients, Brain tumor in children, Diseases [C] - Cancer [C04]
 
 
FIREFLY 1, NCT04775485: A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
2
141
Europe, Canada, US, RoW
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc., Pacific Pediatric Neuro-Oncology Consortium
Low-grade Glioma, Advanced Solid Tumor
05/27
05/27
NCT05287295: A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Not yet recruiting
2
28
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
Children's Oncology Group
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
NCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
2
48
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Lumbar Puncture, LP, Spinal Tap, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
09/28
09/28
PNOC029, NCT05465174: Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
57
US
Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
FIRELIGHT-1, NCT04985604: Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Active, not recruiting
1/2
168
Europe, Canada, US, RoW
Tovorafenib, Pimasertib
Day One Biopharmaceuticals, Inc.
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
07/25
12/25
NCT06965114: Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment

Not yet recruiting
1/2
78
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
03/30
03/30
VICTORY, NCT06381570: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
1
57
Canada
Tovorafenib, Vinblastine
Daniel Morgenstern, The Hospital for Sick Children
Low-grade Glioma
03/27
03/29
PNOC014, NCT03429803: DAY101 In Gliomas and Other Tumors

Active, not recruiting
1
44
US
DAY101, MLN2480, TAK-580
Karen D. Wright, MD, PLGA Fund at Pediatric Brain Tumor Foundation, National Cancer Institute (NCI), Pacific Pediatric Neuro-Oncology Consortium, Team Jack Foundation, Day One Biopharmaceuticals, Inc.
Low-grade Glioma
12/25
12/25
NCT05760586: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing
N/A
NA
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc.
Low-grade Glioma
 
 
Qinprezo (vosaroxin) / Denovo
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Completed
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
2015-004066-28: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 Studie mit einem Dosisfindungsteil gefolgt von einem Phase II-Teil zu Vosaroxin in Kombination mit Azacitidin bei Patienten mit akuter myeloischer Leukämie und intermediärem bzw. ungünstigem genetischem Risiko oder myelodysplastischen Syndrom mit Exzess von Blasten (MDS-EB-2) (AMLSG 24-15)

Not yet recruiting
2
168
Europe
Azacitidine, Vosaroxin, not applicalbe, Powder for injection, Injection, Vidaza
University Hospital Ulm, SUNESIS PHARMACEUTICALS, INC, University Hospital Ulm
Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) Patienten mit bestätigter Diagnose einer akuten myeloischen Leukämie (WHO 2016) und intermediärem oder ungünstigem genetischem Risiko (entsprechend den ELN Empfehlungen 2017); oder Patienten mit myelodysplastischem Syndrom mit Exzess von Blasten (MDS-EB-2), Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Patienten mit Neu diagnostizierte akute myeloische Leukämie oder myelodysplastisches Syndrom mit Exzess von Blasten (MDS-EB-2), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Checkmark For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Jun 2017 - Jun 2017: For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Checkmark ASH 2015
Dec 2015 - Dec 2015: ASH 2015
Completed
1
35
US
vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin
Washington University School of Medicine, Sunesis Pharmaceuticals
Myelodysplastic Syndromes
12/16
04/24
nanatinostat (VRx-3996) / Viracta Therap
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma

Ongoing
2
60
Europe
CHR-3996, Tosedostat, CHR-3996, CHR-2797,
University of Leeds
Relpsed or refractory multiple myeloma
 
 
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”)

Not yet recruiting
2
150
Europe
Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04]
 
 
NAVAL-1, NCT05011058 / 2020-005197-10: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Terminated
2
102
Europe, Canada, US, RoW
Nanatinostat in combination with valganciclovir
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS
12/24
01/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
NCT06302140: A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Recruiting
1
14
Europe
[14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir, Single-agent Nanatinostat (free base) tablets
Viracta Therapeutics, Inc.
Advanced Cancer
02/25
10/25
VT3996-301, NCT05166577: Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Terminated
1
26
Canada, US, RoW
Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda
Viracta Therapeutics, Inc.
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
10/24
01/25
vecabrutinib (SNS-062) / Viracta Therap
No trials found
SNS-229 / Takeda
No trials found
VRx-510 / Viracta Therap
No trials found
arginine butyrate (HQK-1004) / Boston University, Viracta Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ojemda (tovorafenib) / Day One Biopharma
LOGGIC, NCT05566795 / 2022-001363-27: DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (/FIREFLY-2)

Recruiting
3
400
Europe, Canada, US, RoW
Tovorafenib, DAY101, Ojemda, Chemotherapeutic Agent, COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin
Day One Biopharmaceuticals, Inc., SIOPe Brain Tumor Group LOGGIC Consortium
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
02/26
03/30
2020-003657-30: A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer

Ongoing
2
60
Europe
DAY101, Tablet
DOT Therapeutics-1 Inc. (Day One), DOT Therapeutics-1 Inc. (Day One)
BRAF-Altered, Recurrent or Progressive Low-Grade Glioma in pediatric patients, Brain tumor in children, Diseases [C] - Cancer [C04]
 
 
FIREFLY 1, NCT04775485: A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
2
141
Europe, Canada, US, RoW
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc., Pacific Pediatric Neuro-Oncology Consortium
Low-grade Glioma, Advanced Solid Tumor
05/27
05/27
NCT05287295: A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Not yet recruiting
2
28
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
Children's Oncology Group
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
NCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
2
48
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Lumbar Puncture, LP, Spinal Tap, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
09/28
09/28
PNOC029, NCT05465174: Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
57
US
Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
FIRELIGHT-1, NCT04985604: Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Active, not recruiting
1/2
168
Europe, Canada, US, RoW
Tovorafenib, Pimasertib
Day One Biopharmaceuticals, Inc.
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
07/25
12/25
NCT06965114: Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment

Not yet recruiting
1/2
78
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
03/30
03/30
VICTORY, NCT06381570: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
1
57
Canada
Tovorafenib, Vinblastine
Daniel Morgenstern, The Hospital for Sick Children
Low-grade Glioma
03/27
03/29
PNOC014, NCT03429803: DAY101 In Gliomas and Other Tumors

Active, not recruiting
1
44
US
DAY101, MLN2480, TAK-580
Karen D. Wright, MD, PLGA Fund at Pediatric Brain Tumor Foundation, National Cancer Institute (NCI), Pacific Pediatric Neuro-Oncology Consortium, Team Jack Foundation, Day One Biopharmaceuticals, Inc.
Low-grade Glioma
12/25
12/25
NCT05760586: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing
N/A
NA
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc.
Low-grade Glioma
 
 
Qinprezo (vosaroxin) / Denovo
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Completed
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
2015-004066-28: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 Studie mit einem Dosisfindungsteil gefolgt von einem Phase II-Teil zu Vosaroxin in Kombination mit Azacitidin bei Patienten mit akuter myeloischer Leukämie und intermediärem bzw. ungünstigem genetischem Risiko oder myelodysplastischen Syndrom mit Exzess von Blasten (MDS-EB-2) (AMLSG 24-15)

Not yet recruiting
2
168
Europe
Azacitidine, Vosaroxin, not applicalbe, Powder for injection, Injection, Vidaza
University Hospital Ulm, SUNESIS PHARMACEUTICALS, INC, University Hospital Ulm
Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) Patienten mit bestätigter Diagnose einer akuten myeloischen Leukämie (WHO 2016) und intermediärem oder ungünstigem genetischem Risiko (entsprechend den ELN Empfehlungen 2017); oder Patienten mit myelodysplastischem Syndrom mit Exzess von Blasten (MDS-EB-2), Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Patienten mit Neu diagnostizierte akute myeloische Leukämie oder myelodysplastisches Syndrom mit Exzess von Blasten (MDS-EB-2), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Checkmark For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Jun 2017 - Jun 2017: For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Checkmark ASH 2015
Dec 2015 - Dec 2015: ASH 2015
Completed
1
35
US
vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin
Washington University School of Medicine, Sunesis Pharmaceuticals
Myelodysplastic Syndromes
12/16
04/24
nanatinostat (VRx-3996) / Viracta Therap
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma

Ongoing
2
60
Europe
CHR-3996, Tosedostat, CHR-3996, CHR-2797,
University of Leeds
Relpsed or refractory multiple myeloma
 
 
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”)

Not yet recruiting
2
150
Europe
Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04]
 
 
NAVAL-1, NCT05011058 / 2020-005197-10: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Terminated
2
102
Europe, Canada, US, RoW
Nanatinostat in combination with valganciclovir
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS
12/24
01/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
NCT06302140: A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Recruiting
1
14
Europe
[14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir, Single-agent Nanatinostat (free base) tablets
Viracta Therapeutics, Inc.
Advanced Cancer
02/25
10/25
VT3996-301, NCT05166577: Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Terminated
1
26
Canada, US, RoW
Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda
Viracta Therapeutics, Inc.
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
10/24
01/25
vecabrutinib (SNS-062) / Viracta Therap
No trials found
SNS-229 / Takeda
No trials found
VRx-510 / Viracta Therap
No trials found
arginine butyrate (HQK-1004) / Boston University, Viracta Therap
No trials found

Download Options